Biogen Inc. (BIIB)
NASDAQ: BIIB
· Real-Time Price · USD
124.71
-2.33 (-1.83%)
At close: Jun 23, 2025, 2:41 PM
Biogen Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fumarate Revenue | 1.6B | 1.59B | 2B | 2.36B | 3.91B | 2.1B | 2.36B | 883.7M | 4.6M | 1.89B | 1.96B | 1.53B | 1.14B | 1.08B | 900.2M |
| Fumarate Revenue Growth | +0.40% | -20.45% | -15.45% | -39.51% | +85.81% | -11.05% | +167.40% | +19110.87% | -99.76% | -3.75% | +28.37% | +34.39% | +5.22% | +19.92% | n/a |
| Interferon Revenue | 968M | 1.11B | 1.31B | 1.57B | 1.88B | 8.53B | 8.6B | 1.97B | 1.96B | n/a | n/a | n/a | n/a | n/a | n/a |
| Interferon Revenue Growth | -12.45% | -15.30% | -16.65% | -16.59% | -77.99% | -0.77% | +335.62% | +0.47% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| MS Product Revenues Revenue | 4.35B | 4.66B | 5.43B | 6.1B | 7.83B | 2.1B | 1.72B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| MS Product Revenues Revenue Growth | -6.69% | -14.15% | -10.93% | -22.16% | +273.49% | +21.62% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| SPINRAZA Revenue | 1.57B | 1.74B | 1.79B | 1.91B | 2.05B | 1.89B | 1.86B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| SPINRAZA Revenue Growth | -9.65% | -2.92% | -5.86% | -7.16% | +8.45% | +1.51% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TYSABRI product Revenue | 1.72B | 1.88B | 2.03B | 2.06B | 1.95B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TYSABRI product Revenue Growth | -8.63% | -7.58% | -1.56% | +6.01% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 3.98B | 3.14B | 3.47B | 3.81B | 5.9B | 6.71B | 1.9B | 3.34B | 2.77B | 2.64B | 2.64B | 3.58B | 1.99B | 1.88B | 1.74B |
| Non-Us Revenue Growth | +26.57% | -9.45% | -8.84% | -35.50% | -12.12% | +252.73% | -42.97% | +20.60% | +4.72% | +0.23% | -26.37% | +80.01% | +5.74% | +7.85% | n/a |
| United States Revenue | 2.19B | n/a | n/a | n/a | n/a | n/a | n/a | 3.29B | 3.17B | 2.91B | 2.43B | n/a | 2.18B | 1.95B | n/a |
| United States Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | +3.93% | +8.98% | +19.85% | n/a | n/a | +11.36% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 572.5M | 680M | 588.4M | 553.8M | 581.5M | 608.5M | 788.2M | 548M | 605M | 632.8M | 563.3M | 572.6M | 634.9M | 787.9M | 654.1M | 637.3M | 595M | 806.3M | 573.1M | 555.1M | 570.1M | 664.9M | 554.5M | 587.6M | 567.7M | 591.1M | 497.7M | 516.2M | 501.3M | 572.4M | 433.8M | 430.2M | 499.1M | 495.5M | 462.7M | 492.4M | 497.3M | 583M | 477.83M | 491.89M | 560.36M |
| Selling, General, and Administrative Revenue Growth | -15.81% | +15.57% | +6.25% | -4.76% | -4.44% | -22.80% | +43.83% | -9.42% | -4.39% | +12.34% | -1.62% | -9.81% | -19.42% | +20.46% | +2.64% | +7.11% | -26.21% | +40.69% | +3.24% | -2.63% | -14.26% | +19.91% | -5.63% | +3.51% | -3.96% | +18.77% | -3.58% | +2.97% | -12.42% | +31.95% | +0.84% | -13.80% | +0.73% | +7.09% | -6.03% | -0.99% | -14.70% | +22.01% | -2.86% | -12.22% | n/a |
| Research and Development Revenue | 434.1M | 532.3M | 542.7M | 513.9M | 445.4M | 647.5M | 736.3M | 584.2M | 570.6M | 601.6M | 549.2M | 528.6M | 551.7M | 699.5M | 702.4M | 585.1M | 514.2M | 1.73B | 1.14B | 647.6M | 476.3M | 691.7M | 540.4M | 484.8M | 563.7M | 611.6M | 507.9M | 981M | 496.7M | 587.6M | 446.4M | 796.2M | 423.4M | 533.9M | 529M | 473.1M | 437.3M | 541.7M | 519.86M | 490.73M | 460.55M |
| Research and Development Revenue Growth | -18.45% | -1.92% | +5.60% | +15.38% | -31.21% | -12.06% | +26.04% | +2.38% | -5.15% | +9.54% | +3.90% | -4.19% | -21.13% | -0.41% | +20.05% | +13.79% | -70.21% | +51.28% | +76.17% | +35.96% | -31.14% | +28.00% | +11.47% | -14.00% | -7.83% | +20.42% | -48.23% | +97.50% | -15.47% | +31.63% | -43.93% | +88.05% | -20.70% | +0.93% | +11.82% | +8.19% | -19.27% | +4.20% | +5.94% | +6.55% | n/a |